← all works
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet Oncology
- Topic
- HER2/EGFR in Cancer Research
- Field
- Medicine
- Canadian institutions
- Hôpital du Saint-Sacrement
- Funders
- —
- Keywords
- PertuzumabTrastuzumabDocetaxelMedicineInternal medicineClinical endpointBreast cancerOncologyPopulationChemotherapyClinical trialCancer
- Has abstract in OpenAlex
- no